STOP ‐ing Rheumatoid Arthritis—Lessons Learned From the Latest Prevention Trial
- 9 December 2025
- journal article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (4) , 788-790
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid ArthritisArthritis & Rheumatology, 2026
- A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete LupusArthritis & Rheumatology, 2025
- EULAR /American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of ArthralgiaArthritis & Rheumatology, 2025
- Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trialThe Lancet Rheumatology, 2024
- Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trialThe Lancet, 2024
- Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trialThe Lancet, 2024
- Preventive interventions in individuals at risk for Rheumatoid Arthritis: State of the art and perspectivesJoint Bone Spine, 2023
- Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trialThe Lancet, 2022
- Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI studyAnnals of the Rheumatic Diseases, 2019
- A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA studyThe American Journal of Medicine, 1995